Further reading
- Gregg RW, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;10:795–803
- Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes. Eur J Cancer 2005;64(1):26–31
- Dina OA, Chen X, Reichling D, Levine JD. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001;108:507–515
- Stubblefield MD, et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuro-pathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005;17:271–276
- Openshaw H, et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: Lack of neuro-protective effect of amifostine. Clin Cancer Res 2004;10: 461–467
- Vahdat L, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001;7:1192–1197
- Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997;67: 172–177
- Satya-Murti S, Howard L, Krohel G, Wolf B. The spectrum of neurologic disorder from vitamin E deficiency. Neurol-ogy 1986;36:917–921
- Pace A, et al. Neuroprotective effect of vitamin E supple-mentation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21:927–931